Highlight
- Initial statin-ezetimibe combination therapy lowers LDL cholesterol more effectively than statin monotherapy among patients with atherosclerotic cardiovascular disease (ASCVD).
- No significant difference in the 3-year composite risk of major cardiovascular events between combination therapy and monotherapy groups.
- Combination therapy facilitates achieving lower LDL-C targets within both intensive and conventional LDL-C-targeting strategies.
- Safety profiles of combination therapy and monotherapy are comparable over the 3-year follow-up.
Study Background
Specialty calculators
For clinical reference; use professional judgment.
